They probably get their own table, but in some views (like the oncoprint view) it should be treated the same as a mutation. Also, there are some grouping issues. PML-RARA is straightforward enough, but MLL has many partners and they're usually pooled together as "MLL fusions" or similar. This has some similarities to the specific subclasses of the mutations that we want to split out
They probably get their own table, but in some views (like the oncoprint view) it should be treated the same as a mutation. Also, there are some grouping issues. PML-RARA is straightforward enough, but MLL has many partners and they're usually pooled together as "MLL fusions" or similar. This has some similarities to the specific subclasses of the mutations that we want to split out